Oralair

Allergen extract from pollen of Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis, the active ingredient in Oralair, is an allergen immunotherapy presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis and grass‑pollen‑induced allergic rhinoconjunctivitis in patients with documented grass pollen sensitivity.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oralair is used in allergen immunotherapy to modify the immune response to grass pollen exposure. - Seasonal allergic rhinitis (grass pollen): Reduces nasal congestion, sneezing, itching and improves overall symptom control during the grass pollen season. - Grass pollen‑induced allergic rhinoconjunctivitis: Alleviates ocular irritation and conjunctival symptoms while promoting long‑term tolerance to grass pollen allergens. - Preventive management of grass pollen allergy: Decreases the need for rescue medication and enhances quality of life for affected individuals.

Oralair may cause adverse reactions, most of which are mild and localized.

Common Side Effects: - Oral itching or tingling: mild discomfort in the mouth after tablet placement. - Throat irritation: transient soreness or scratchy sensation. - Mouth edema: slight swelling of the lips or tongue. - Mild gastrointestinal upset: occasional nausea or abdominal discomfort. - Headache: transient mild headache.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Systemic allergic reaction: widespread urticaria, bronchospasm, or hypotension. - Angioedema: rapid swelling of face, lips, or airway. - Severe asthma exacerbation: worsening of asthma symptoms requiring emergency care.

Before prescribing Oralair, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: discuss potential risks with a healthcare professional. - Concomitant immunotherapy: avoid simultaneous use of other allergen immunotherapies. - Uncontrolled asthma: contraindicated in patients with severe, uncontrolled asthma. - Age and suitability: prescribe only for patients for whom the prescriber determines appropriate use. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Oralair may interact with certain medications, requiring careful management.

Major Interactions (Avoid): - Beta‑blockers: may increase severity of anaphylactic reactions. - Immunosuppressants: may diminish the therapeutic effect of the tablet.

Moderate Interactions (Monitor Closely): - Antihistamines: can mask early signs of an allergic reaction. - Systemic corticosteroids: may alter immune response to the allergen extract. - Other sublingual immunotherapy products: concurrent use may raise risk of overlapping exposure and adverse events.